Literature DB >> 12829842

Generation of influenza A viruses with chimeric (type A/B) hemagglutinins.

Taisuke Horimoto1, Ayato Takada, Kiyoko Iwatsuki-Horimoto, Masato Hatta, Hideo Goto, Yoshihiro Kawaoka.   

Abstract

To gain insight into the intertypic incompatibility between type A and B influenza viruses, we focused on the hemagglutinin (HA) gene, systematically studying the compatibility of chimeric (type A/B) HAs with a type A genetic background. An attempt to generate a reassortant containing an intact type B HA segment in a type A virus background by reverse genetics was unsuccessful despite transcription of the type B HA segment by the type A polymerase complex. Although a type A virus with a chimeric HA segment comprising the entire coding sequence of the type B HA flanked by the noncoding sequence of the type A HA was viable, it replicated only marginally. Other chimeric viruses contained type A/B HAs possessing the type A noncoding region together with either the signal peptide or transmembrane/cytoplasmic region of type A virus or both, with the remaining regions derived from the type B HA. Each of these viruses grew to median tissue culture infectious doses of more than 10(5) per ml, but those with more type A HA regions replicated better, suggesting protein-protein interactions or increased HA segment incorporation into virions as contributing factors in the efficient growth of this series of viruses. All of these chimeric (A/B) HA viruses were attenuated in mice compared with wild-type A or B viruses. All animals intranasally immunized with a chimeric virus survived upon challenge with a lethal dose of wild-type type B virus. These results suggest a framework for the design of a novel live vaccine virus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829842      PMCID: PMC161929          DOI: 10.1128/jvi.77.14.8031-8038.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  An analysis of the role of neuraminidase in the receptor-binding activity of influenza B virus: the inhibitory effect of Zanamivir on haemadsorption.

Authors:  C Luo; E Nobusawa; K Nakajima
Journal:  J Gen Virol       Date:  1999-11       Impact factor: 3.891

Review 2.  Replication of orthomyxoviruses.

Authors:  A Portela; T Zürcher; A Nieto; J Ortín
Journal:  Adv Virus Res       Date:  1999       Impact factor: 9.937

Review 3.  Functional balance between haemagglutinin and neuraminidase in influenza virus infections.

Authors:  Ralf Wagner; Mikhail Matrosovich; Hans-Dieter Klenk
Journal:  Rev Med Virol       Date:  2002 May-Jun       Impact factor: 6.989

4.  Influenza virus assembly and lipid raft microdomains: a role for the cytoplasmic tails of the spike glycoproteins.

Authors:  J Zhang; A Pekosz; R A Lamb
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 5.  The development of live attenuated cold-adapted influenza virus vaccine for humans.

Authors:  H F Maassab; M L Bryant
Journal:  Rev Med Virol       Date:  1999 Oct-Dec       Impact factor: 6.989

6.  Generation of influenza A viruses entirely from cloned cDNAs.

Authors:  G Neumann; T Watanabe; H Ito; S Watanabe; H Goto; P Gao; M Hughes; D R Perez; R Donis; E Hoffmann; G Hobom; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

7.  Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein.

Authors:  A Ali; R T Avalos; E Ponimaskin; D P Nayak
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus.

Authors:  L J Mitnaul; M N Matrosovich; M R Castrucci; A B Tuzikov; N V Bovin; D Kobasa; Y Kawaoka
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

9.  Comparative analysis of the ability of the polymerase complexes of influenza viruses type A, B and C to assemble into functional RNPs that allow expression and replication of heterotypic model RNA templates in vivo.

Authors:  B Crescenzo-Chaigne; N Naffakh; S van der Werf
Journal:  Virology       Date:  1999-12-20       Impact factor: 3.616

Review 10.  Live attenuated vaccines against influenza; an historical review.

Authors:  M D Wareing; G A Tannock
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

View more
  6 in total

1.  Limited compatibility of polymerase subunit interactions in influenza A and B viruses.

Authors:  Kerstin Wunderlich; Mindaugas Juozapaitis; Benjamin Mänz; Daniel Mayer; Veronika Götz; Andrea Zöhner; Thorsten Wolff; Martin Schwemmle; Arnold Martin
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

2.  A reassortment-incompetent live attenuated influenza virus vaccine for protection against pandemic virus strains.

Authors:  Rong Hai; Adolfo García-Sastre; David E Swayne; Peter Palese
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

Review 3.  Influenza B: Prospects for the Development of Cross-Protective Vaccines.

Authors:  Liudmila M Tsybalova; Liudmila A Stepanova; Edward S Ramsay; Andrey V Vasin
Journal:  Viruses       Date:  2022-06-17       Impact factor: 5.818

4.  Limited compatibility between the RNA polymerase components of influenza virus type A and B.

Authors:  Kiyoko Iwatsuki-Horimoto; Yasuko Hatta; Masato Hatta; Yukiko Muramoto; Hualan Chen; Yoshihiro Kawaoka; Taisuke Horimoto
Journal:  Virus Res       Date:  2008-05-02       Impact factor: 3.303

5.  Influenza A and B virus intertypic reassortment through compatible viral packaging signals.

Authors:  Steven F Baker; Aitor Nogales; Courtney Finch; Kevin M Tuffy; William Domm; Daniel R Perez; David J Topham; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

6.  Functional chimeras of human immunodeficiency virus type 1 Gp120 and influenza A virus (H3) hemagglutinin.

Authors:  K M Copeland; A J Elliot; R S Daniels
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.